Expression of vascular endothelial growth factor receptor‐1 and ‐2 in normal and diseased canine eyes

Binder, Daniel; Herring, Ian P.; Zimmerman, Kurt; Pickett, J. Phillip; Huckle, William R.

doi:10.1111/j.1463-5224.2011.00973.x

Cited by 12 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4. The presence of vascular endothelial growth factor (VEGF) in the AH, as well as VEGF receptors 1 and 2 in PIFMs, has been documented in canine PACG, 42,44 and likely plays a role in canine PIFM formation. In addition, macrophages may directly participate in the process of fibrovascular tissue proliferation, either through cell-cell signaling to fibroblasts and/or through macrophage differentiation into fibroblasts under appropriate conditions.…”

Section: Pathology Of Primary Canine Glaucomamentioning

confidence: 97%

Microscopic Lesions in Canine Eyes with Primary Glaucoma

Beamer

Reilly

Pizzirani

2015

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Section: Pathology Of Primary Canine Glaucomamentioning

confidence: 97%

Microscopic Lesions in Canine Eyes with Primary Glaucoma

Beamer

Reilly

Pizzirani

2015

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

“…As VEGF has a physiological role as angiogenetic and neuroprotective agent in both choriocapillaris and neurosensory retina [16-19], it is discussed whether RPE atrophy is accelerated by anti-VEGF treatments or is part of the natural course of advanced AMD [6-12]. …”

Section: Introductionmentioning

confidence: 99%

Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration

Sitnilska¹,

Altay²,

Enders³

et al. 2018

Ophthalmologica

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate risk factors for the development of retinal pigment epithelium (RPE) atrophy in patients with neovascular age-related macular degeneration (nAMD). Procedures: This post hoc analysis of the prospective RESPONSE study includes 52 therapy-naive nAMD patients without baseline RPE atrophy, who were treated with ≥9 anti-vascular endothelial growth factor (VEGF) injections for ≥3 years. RPE atrophy was assessed via multimodal imaging. Baseline aqueous VEGF and serum complement levels (C3d/C3) were measured. Risk factors for atrophy development were evaluated via logistic regression analysis. Results: Atrophy onset was significantly associated with the duration of nAMD (mean 5.34 years; odds ratio = 1.83, p = 0.012). Anti-VEGF injection number, age, C3d/C3 ratio, baseline intraocular VEGF, or delay to the first treatment had no influence on RPE atrophy. Conclusions: The duration of treatment-requiring nAMD was identified as primary risk factor for the onset of concomitant RPE atrophy after commencing therapy. Targeting concomitant atrophy in nAMD patients might improve the long-term prognosis of the disease.

show abstract

“…The VEGF receptors -1 (VEGFR1) and -2 (VEGFR2) have been detected in pathological vascular endothelium associated with corneal neovascularisation in dogs (Binder et al, 2011). The results of this study suggest a role of VEGF receptors in both physiological and pathological angiogenesis in canine ocular tissue.…”

mentioning

confidence: 55%

Serum vascular endothelial growth factor concentration in dogs diagnosed with chronic superficial keratitis

Balicki

Sobczyńska-Rak

2014

Acta Veterinaria Hungarica

View full text Add to dashboard Cite

The objective of this study was to measure the vascular endothelial growth factor (VEGF) levels in dogs diagnosed with chronic superficial keratitis (CSK). The study was performed on 25 German shepherds (14 males and 11 females, aged between 3 and 11 years). The VEGF levels were determined in blood serum using commercially available enzyme-linked immunosorbent assay (ELISA; Quantikine Canine VEGF Immunoassay, R&D Systems). The test group of affected German shepherds was subdivided into two subgroups, based on the area of corneal neovascularisation. The first subgroup (9 patients) comprised dogs with neovascularisation observed in 1 to 2 quadrants of the right and left cornea, while the second subgroup (16 patients) comprised dogs with neovascularisation observed in 3 to 4 quadrants of the right and left cornea. The control group comprised 12 clinically healthy German shepherds (7 males and 5 females, aged between 3 and 9 years). The results were then statistically analysed by the Mann-Whitney test. The study indicated that the median serum VEGF concentration in healthy dogs was 14.9 pg/mL. The VEGF level observed in sick German shepherds was elevated (19.5 pg/mL) as compared to the values found in healthy dogs; however, a statistically significant increase in VEGF concentration, as compared to the values observed in healthy dogs, was only noted in the first subgroup, where the median VEGF concentration was 22.0 pg/mL. Elevated serum VEGF concentration was observed in German shepherds diagnosed with CSK. A statistically significant increase in VEGF levels was observed in dogs in the first stage of the disease, i.e. the early stage of neovascularisation.

show abstract

Expression of vascular endothelial growth factor receptor‐1 and ‐2 in normal and diseased canine eyes

Abstract: The results of this study suggest a role for VEGF receptors in both physiologic and pathologic angiogenesis in canine ocular tissue. Manipulation of this pathway may be a rational consideration for therapeutic intervention in canine ocular disease exhibiting pathologic neovascularization.

Cited by 12 publications

References 55 publications

Microscopic Lesions in Canine Eyes with Primary Glaucoma

Microscopic Lesions in Canine Eyes with Primary Glaucoma

Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration

Serum vascular endothelial growth factor concentration in dogs diagnosed with chronic superficial keratitis

Contact Info

Product

Resources

About